A device for radio frequency ablation, configured to deliver a direct current, an alternating current, and a radio frequency energy to a lesion for treating a pulmonary disease. The device for radio frequency ablation can determine the effectiveness of an ablation according to one or more of a fall in impedance, a rate of change in impedance, a change in the rate of change in impedance, or a change from falling in impedance to rising in impedance. The device for radio frequency ablation uses a segmentation control method and dynamic smoothing for adjusting a radio frequency output power to control an ablation temperature, and the tissue to be ablated is prevented from being quickly heated in short time, to ensure a smooth change in the radio frequency output power in the ablation process. The device for radio frequency ablation further comprises a specific protection mechanism for preventing repeated ablation. The temperature of an ablation site is detected before each ablation, and ablation will not be performed if the temperature of the ablation site is higher than 40° C. to 60° C. Also disclosed is a multi-electrode ablation device comprising the device for radio frequency ablation.

Endolumenal devices and methods can be used for the treatment of health conditions including obesity and diabetes. In some embodiments, the methods and systems provided herein can cause weight loss or control diabetes by reducing the caloric absorption of an individual. For example, this document provides several devices and methods for treating obesity and diabetes by using electroporation to modulate the duodenal mucosa. In addition, this document provides devices and methods for bypassing portions of the gastrointestinal tract to reduce nutritional uptake.

Devices and systems for the selective positioning of an intravascular neuromodulation device are disclosed herein. Such systems can include, for example, an elongated shaft and a therapeutic assembly carried by a distal portion of the elongated shaft. The therapeutic assembly is configured for delivery within a blood vessel. The therapeutic assembly can include a pre-formed shape and can be transformable between a substantially straight delivery configuration; and a treatment configuration having the pre-formed helical shape to position the therapeutic assembly in stable contact with a wall of the body vessel. The therapeutic assembly can also include a mechanical decoupler operably connected to the therapeutic assembly that is configured to absorb at least a portion of a force exerted on the therapeutic assembly by the shaft so that the therapeutic assembly maintains a generally stationary position relative to the target site.

Systems, apparatuses, and methods for treating a patent foramen ovale (PFO) of a patient. A system may include a catheter configured to extend within at least a portion of the patients heart. One or more stabilizer balloons may be coupled to the catheter and configured to be positioned within a tunnel of the patent foramen ovale and inflated to apply a force to at least one of a septum primum or a septum secundum of the patients heart. An injection device may be configured to inject material into at least one of the septum primum or the septum secundum to cause swelling of the injected septum primum or the injected septum secundum in a direction towards the opposing septum primum or the opposing septum secundum.

The present invention is directed to a method of endoscopically ablating/resecting/excluding (A/R/E) the mucosa of the gastric fundus and body. The method of the present invention is intended to cause cellular death to the X/A-like, ghrelin producing and other hormone cells. This is in contrast to present methods to provide only transient ischemia. The use of the method of the present invention results in a more permanent and robust method of reducing ghrelin and other hormone levels. In addition, a method according to the present invention can be used to induce scarring of the gastric fundus which will reduce gastric accommodation of excess food and result in early satiety.

A method of creating a shunt between a right atrium and a left atrium of a mammalian heart including puncturing an atrial septum between the right atrium and the left atrium to create a shunt. An ablation device having balloon is advanced at least partially through the shunt. The balloon is inflated and configured to thermally isolate the atrial septum from blood within the left atrium and the right atrium. Ablation energy is delivered to ablate the atrial septum.

The present disclosure relates to the field of tissue mapping and ablation. Specifically, the present disclosure relates to expandable medical devices for identifying and treating local anatomical abnormalities within a body lumen. More specifically, the present disclosure relates to systems and methods of focal treatment for overactive bladders.

Systems, devices, and methods for electroporation ablation therapy are disclosed, with the device including a set of splines coupled to a catheter for medical ablation therapy. Each spline of the set of splines may include a set of electrodes formed on that spline. The set of splines may be configured for translation to transition between a first configuration and a second configuration. The devices described herein may be used to form a lesion via focal ablation.

Devices and systems for the selective positioning of an intravascular neuromodulation device are disclosed herein. Such systems can include, for example, an elongated shaft and a therapeutic assembly carried by a distal portion of the elongated shaft. The therapeutic assembly is configured for delivery within a blood vessel. The therapeutic assembly can include one or more energy delivery elements configured to deliver therapeutic energy to nerves proximate a vessel wall.

Devices for therapeutic nasal neuromodulation and associated systems and methods are disclosed herein. A system for therapeutic neuromodulation in a nasal region configured in accordance with embodiments of the present technology can include, for example, a shaft and a therapeutic element at a distal portion of the shaft. The shaft can locate the distal portion intraluminally at a target site inferior to a patient's sphenopalatine foramen. The therapeutic element can include an energy delivery element configured to therapeutically modulate postganglionic parasympathetic nerves at microforamina of a palatine bone of the human patient for the treatment of rhinitis or other indications. In other embodiments, the therapeutic element can be configured to therapeutically modulate nerves that innervate the frontal, ethmoidal, sphenoidal, and maxillary sinuses for the treatment of chronic sinusitis.